Prothena reports Q4 net income $6.3M, full year net loss $116.9M; provides 2023 guidance

PROTHENA CORP PUBLIC LTD CO

2022-FY EPS reported -$2.47 revenue$53,905,000

Q4 2022 revenue $49.9M (incl. $40M Novo Nordisk milestone); full year revenue $53.9M vs $200.6M in 2021.
Cash, cash equivalents and restricted cash $712.6M at Dec 31, 2022; no debt.
2023 guidance: net cash used in operating/investing $213-229M; year-end cash ~$512M.
PRX012 Phase 1 topline data expected year-end 2023; PRX005 Phase 1 MAD topline also year-end 2023.
Birtamimab Phase 3 AFFIRM-AL topline data expected 2024; prasinezumab Phase 2b topline 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.